Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
you know what...I disagree with you just a little bit...here is why...I think Nuvilex is the perfect first bio for the squeamish because after investing in the bio's I have ...this one is going far...and the newbies will make a bunch of money in perspective to what they invested..and hopefully they will talk with a long investor to mentor them...but in a learning experience...for newbies either to the market or to bio's...maybe not a good lesson to hit a home run on a under the radar hidden gem...but we have all lost money on stocks...somebody I admire told me "The best lesson learned is when you lose money"...and the stock market has taught me that is true...so invest what you can lose but do not be afraid to take risk or you will never have the thing you deserve...and so do your DD on Nuvilex or any stocks you own and don't listen to all the noise...
thing are going to happen with Nuvilex very very soon...
bull
Thanks for the post...it definitely helps for any one new or any one that still does not understand the advances that Nuvilex has made...so much appreciated ...
bull
I am patiently waiting for the results of the TD2 study...it should not be long...I think we should be hearing something on Diabetes soon...Diabetes will be the game changer for Nuvilex ...I have always said that and believe that...the CiaB for pancreatic cancer has proven better than the 2 gold standards and will extend life although short and give quality of life better than the others...but the proof of concept is there for Diabetes... for Nuvilex to just take it and run with it...think about it...no more shots for Type I Diabetes...I feel sorry for those living with it...Nuvilex with CiaB is a cure not just an extension of quality of life...
bull
Nuvilex was on the OTCQB and still is on the OTCQB with their new stricter rules for the OTC...so all is good for Nuvilex...
bull
I just added to my position...I am not waiting...and we are due for some news..
Nuvilex
bull
This is just a formality to show that Nuvilex complies with the new OTC rules that they have been rolling out this year...we were and still are on the OTCQB...this will explain it for you....
http://hosted.verticalresponse.com/327098/595f8d418d/318056815/90a8b32497/
bull
OTC Disclosure & News Service
Share on Facebook Share on Twitter Share on LinkedIn
OTC Markets Group Welcomes Nuvilex to OTCQB
Aug 28, 2014
OTC Disclosure & News Service
New York, NY -
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Nuvilex, Inc. (OTCQB: NVLX) is verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, as of August 28, 2014.
Nuvilex is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the widely-used anticancer prodrug ifosfamide together with encapsulated live cells, which convert ifosfamide into its active or"cancer-killing" form. Nuvilex is also working towards clinical trials associated with the symptoms of advanced pancreatic cancer and other abdominal cancers.
Nuvilex's subsidiary, Medical Marijuana Sciences, is dedicated to the development of cancer treatments based upon chemical constituents of the cannabis plant known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or eliminating the debilitating side effects usually associated with traditional cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop “green” approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.
bull
Thanks for that because you know and I know but...some do not do their DD...have owned chromadex for a long time and do not post here mainly because I very seldom watch this stock just like my other Frost stocks...found them...did relentless DD on them...bought them and packed them away knowing I would reap the benefit like his other companies he developed and sold...
bull
I don't think nvlx pps is going there....
bull
I totally agree with you...we all know why we own Nuvilex...
bull
That is Deficit not Debt....if you need help understanding the difference there is a lot of good information on the internet on the subject...
Nuvilex
bull
developmental-stage biotechs in trials like Nuvilex are never valued the way you are talking about...there is a lot of info on the internet about that if you need guidance...
bull
We look for a micro cap under the radar company ...and buy into that company at a ridiculously low pps...seriously...look at the pps of this company going into Late Stage Clinical Trials because Nuvilex recognized a great technology and bought it...Austrianova is a company with cancer doctors running the company that did not know how to fund the late stage trials...but NOW...they have Waggoner that has done more for this company and Austrianova's CiaB in the last 9 months than the last 9 years..
And when it comes to a developmental-stage biotech...and they need funding and all the funding they get goes into R&D...some don't get it ...
who would not want to own Nuvilex...if you know bio's...
bull
After the results come in from the TD2 study I am sure they will kick themselves but in perspective anyway someone selling only 47,000 shares...what does that matter to the stock or the company...I am sure the swing traders playing with nvlx have bought and sold that many... thousands of times over...
bull
Here is the article in full....
Biotech firm a leader in cell-encapsulation 21 August 14 The Business Times
TO the naked eye, the capsules produced by biotechnology firm Austrianova look like brightly coloured balls, each barely a millimeter in diameter.
But each one of these capsules is in fact a pod capable of containing 10,000 living cells.
Professor Walter Gunzburg, the chairman and chief technology officer of Austrianova, explained that the capsules are made of a special type of cotton, designed to protect the cells and cocoon them so they can grow and do the job they need to do - for these cells, contained in their pods, are to be injected into the human body for a variety of potential applications - from cancer treatment to probiotics, stem cells and cosmetics.
The special cotton of which the capsules are made also ensure that the body's immune system does not reject the cells, he said.
"We take living cells and we mix them with this cotton material - this special proprietary cotton derivative which we manufacture ourselves. When you mix the two together you form these capsules, with the cells inside."
This is what Austrianova's Cell-in-a-Box or cell encapsulation technology is about - and it could change the way medication is administered to patients.
The capsules are all porous, to allow for the movement of substances in and out. This way, the cells inside can draw nutrition from outside and expel waste; the porous membrane also enables useful substances produced by the cell to enter the body.
Prof Gunzburg said: "What we're doing here is making a mini implant. Instead of manufacturing a pharmaceutical product in a factory, putting it in a bottle, sending it to the hospital and then administering it to the patient, we are actually moving the factory into the patient."
Diabetes patients, for example, are injected with these capsules containing insulin-producing cells, which can be programmed with mechanisms to react to the body, only producing as much insulin as is needed each time.
Dosing in this way will be more precise, compared to the conventional method of making rough estimations for each dose, or relying on a fixed dose regardless of changes in the body.
The system is thus self-regulating, which takes some burden off patients from having to monitor their doses.
Austrianova's most advanced programme so far is in the treatment of pancreatic cancer, which has been in two clinical trials in Europe involving 27 patients with advanced stages of the disease.
Prof Gunzburg said existing drugs have a small effect on one's survival and reduce pain, but cause a range of side effects.
The pancreatic cancer patients have been injected with capsules containing cells that have been genetically modified to activate the chemotherapeutic chemicals these patients are administered.
So the chemotherapy is activated only where these cells land up. Austrianova's chief executive Dr Brian Salmons said: "It's like a magnifying glass, focusing the effect on the tumour. This allows you to go in with a low dose, so that you don't really get many side effects. So you get better anti-tumour activity and fewer side effects as well."
Results of the trials have so far been promising: the patients have a median survival period of 40 weeks, double that of the current gold standard treatment. In eight of the 27 patients, the tumours shrank as well.
Cell-encapsulation pioneer
Austrianova is the only company in the world using its proprietary cotton material to advance cell-encapsulation technology.
The material of which the capsules are made enables the capsules to be frozen and shipped around the world and stored for up to five years. Most other cell products need to be used immediately, making logistics more costly and complicated.
Austrianova's operations are primarily partner-based. The company has around 10 partners worldwide, with whom it conducts research and development and leverages on their expertise in order to deliver a customised product.
"It's very customised. Once the production process is set, it's very simple: you just put the cells and the cotton together at the beginning and the beads come out at the end. But how you tweak the cells, how you tweak the cotton to make the perfect bead for the perfect application, like the size of the bead, the size of the holes - that's all stuff that we tweak," said Prof Gunzburg.
Interestingly, this business model differs from what the founders of Austrianova initially had in mind.
The company rose in Austria, with its original focus being to develop all stages of its product for pancreatic cancer, but this was an extremely costly mission.
Austrianova thus went from developing its own product to being a technology platform, and this is how the company came to be in Singapore, known for its vibrant stem cell community. Singapore became the company's stepping stone into Asia when it set up here in 2007.
But what Singapore lacks, compared to Europe, was a venture capital culture.
Austrianova adapted. It has since built itself here by relying on financing from high-net-worth individuals. It has also placed a premium on avoiding risks and diversifying the company's offerings, instead of being focused on a single product as is the norm in Europe.
Dr Salmons said: "In the past, we used to focus on our oncology product, but now, we've got many horses in the race, different ways to make products and generate income.
"As a company offering a technology platform, we work with other partners who have specific needs. So they have cells which they would like to use for some particular application; they come to us and we co-develop the product with them."
Prof Gunzburg agreed, saying: "The most important thing is to keep the company liquid and move the company forward, and you have to find a way to do that, whatever it takes."
Subsidiary in Thailand
The company's cash flow comes from its clients, who pay for every stage of their product development with Austrianova.
It also places an emphasis on minimising costs and keeping the company's burn rate low by outsourcing functions on a pay-by-use system; it does this with its financial services, business development and legal advice functions.
Austrianova has also set up a subsidiary in Thailand, which it fully owns. This unit concentrates on the manufacturing of medical products for global export and be off the ground by the end of the year.
Thailand was chosen because it is cheaper, more cost-efficient than Singapore, said Prof Gunzburg. The company hopes to begin manufacturing its pancreatic cancer product for further patient trials by the first half of next year.
Dr Salmons said: "Running a company is not just about making money. It is important to bring your investors a return, but it is also because there's a medical need out there for which we want to develop products that will actually help patients eventually."
Prof Gunzburg said: "We're building a company that should grow and be around in 10 years' time. We are trying to build something that is sustainable."
http://www.biotechsingapore.com/SingleNews.aspx?DirID=182&rec_code=961505
bull
Dr Walter Gunzburg hasn't gone anywhere...
Cell-in-a-Box know-how: The key personnel in Austrianova are (from left) chief operating officer Dr John Dangerfield, chairman and chief technology officer Dr Walter Gunzburg and president and chief executive officer Dr Brian Salmons
PUBLISHED AUGUST 21, 2014
Biotech firm a leader in cell-encapsulation
Austrianova runs a tight ship here as it grows its business of delivering medical treatments in 'capsules'. AMANDA EBER reports
PRINT |EMAIL THIS ARTICLE
BT 20140821 AEAUSTRIA 1232201
Cell-in-a-Box know-how: The key personnel in Austrianova are (from left) chief operating officer Dr John Dangerfield, chairman and chief technology officer Dr Walter Gunzburg and president and chief executive officer Dr Brian Salmons - PHOTO: YEN MENG JIIN
TO the naked eye, the capsules produced by biotechnology firm Austrianova look like brightly coloured balls, each barely a millimeter in diameter.
But each one of these capsules is in fact a pod capable of containing 10,000 living cells.
Professor Walter Gunzburg, the chairman and chief technology officer of Austrianova, explained that the capsules are made of a special type of cotton, designed to protect the cells and cocoon them so they can grow and do the job they need to do - for these cells, contained in their pods, are to be injected into the human body for a variety of potential applications - from cancer treatment to probiotics, stem cells and cosmetics.
The special cotton of which the capsules are made also ensure that the body's immune system does not reject the cells, he said.
http://www.businesstimes.com.sg/premium/singapore/biotech-firm-leader-cell-encapsulation-20140821
bull
here are the true figures on short to long volume for the last 2 days....
Symbol Name Short Volume Long Volume Total Volume Short%
2014-08-25 NVLX Nuvilex Inc 784630 2133004 2917634 27
2014-08-22 NVLX Nuvilex Inc 128420 1784650 1913070 7
bull
NUVILEX'S TIME HAS ARRIVED...ignore the noise...TRIALS says it all...
bull
Nuvilex is Astrianova is CiaB is TD2 ...NOW... so everyone needs to get over it because this little bio's time has come about...no matter what the noise says...
bull
I would have to disagree...Nuvilex's pps is going nowhere near that...the last low was .213 closing and bounced from there...so if anyone would want to add to their position... right here is the level you would do it...
bull
Nuvilex is a great find...a hidden gem and if you have ever had one of these hidden gem stocks before like Nuvilex you know what I am talking about...forget the noise.....most of you on here know I chart every stock I own and do DD every day...so as far as the chart goes ...the stock would have done a lot better if it had never gone to .62...and one pr that I don't think was that significant made it run...the significant pr is coming shortly with the results of TD2 study...
bull
I'm glad I own this Nuvilex...I was smart enough to buy it when it is this far under the radar...after the TD2 study that Dr. Von Hoff gives results on...it won't be...
bull
HOFF OVERSEEING TD2 STUDY...this is who you have working on our team...
Many of Dr. Daniel Von Hoff's patients arrive at his clinic awaiting death.
They are losing their battle against cancer and have been told they have only months to live.
Von Hoff has defined his life around these patients. He specializes in the toughest cancer cases, for which conventional therapy has failed. He is especially focused on subduing pancreatic cancer, which kills most people within a year of being diagnosed.
Von Hoff and his team, who work out of a clinic and a laboratory in Scottsdale, are one of the success stories in the decades-long, frustrating war against cancer, whose death toll in the United States is second only to heart disease.
He has been involved in the development of a half-dozen drugs that are routinely used to treat cancer, drugs that have extended people's lives by months and sometimes years.
In the quest to create the most effective medicine, he has worked with other scientists over the years on more than 200 clinical trials, which some cancer researchers say is probably a record.
The breadth of the research has made Von Hoff one of the foremost cancer scientists in the world. In June, the American Society of Clinical Oncology honored him with its most prestigious award in the field of cancer research.
In the past two decades, "he has done more to develop effective cancer drugs than just about anybody else," said Dr. Richard Schilsky, a professor of medicine at the University of Chicago who served on the award-selection committee.
Colleagues describe Von Hoff as a doctor with a profound sense of urgency who works non-stop to get promising drugs from the lab and into clinical trials.
The 63-year-old works nearly every day in his lab near Mayo Clinic in Scottsdale, in his clinic at Scottsdale Healthcare Shea Medical Center or at home. His employer is the Translational Genomics Research Institute in Phoenix, or TGen, where he is physician in chief.
Von Hoff sleeps only three hours a night. He sees dozens of patients a month, advises other doctors on treating patients and oversees the research lab, which identifies potential "target" genes for cancer drugs.
He never loses sight of his patients, colleagues say.
"In the retail world, the customer is the king. For him, patients are the king," said Haiyong Han, who manages Von Hoff's lab.
Jeffrey Trent, president and research director of TGen, calls him the bravest person he has ever met because of the personal care and empathy Von Hoff maintains, year after year, for patients with only a few months to live. He is a kind of a "physician on steroids," Trent said.
"Most researchers say, 'Let's really understand this (drug) completely, and then we can perhaps use it for someone in the clinic.' Dan says, 'We need things for the clinic today. These people are in front of us today. Let's see if we can utilize that today.' "
To begin a clinical trial, researchers must show a drug has a high likelihood of success and a low likelihood of patient complications.
Von Hoff didn't set out with the goal of becoming a cancer doctor. In fact, it was purely an accident. He credits much of his success to a life lesson he learned as a young physician.
Fascinating stuff
The oldest of five children, Von Hoff grew up in east-central Wisconsin, attending a one-room schoolhouse. His father was a bricklayer, and his mother a nurse's aide in a hospital.
He got interested in medicine around the fourth grade, when the polio scare was in full swing. Nurses came to the school to vaccinate the children. The large needles frightened him. He also was fascinated that a simple shot could prevent the dreaded viral disease, which crippled thousands of children in the early and mid-20th century.
After majoring in biology and chemistry in college, he was admitted to Columbia University College of Physicians and Surgeons in New York City in 1969. He soon saw firsthand how anti-cancer drugs could improve patients' lives.
One day, he tagged along with a pediatric oncologist who was treating a 3-year-old with a tumor mushrooming out of her head. The prognosis wasn't good; the child suffered from constant seizures.
The oncologist felt that the child might benefit from an experimental anti-cancer drug. He suggested the drug daunomycin to the girl's parents, who agreed to try it. Within a day, the child's seizures stopped. The next day, she rode a tricycle. Three days later, the parents took their daughter home.
She eventually died from the tumor, but she lived a lot longer than she would have without the treatment. That drug is still being used today.
"Her mom and dad got a chance to know her instead of just a little baby sitting there seizing," Von Hoff said.
The experience had a profound effect on him. But he still wasn't planning to make cancer his life's work. His first choice was studying infectious diseases.
Then a random assignment came his way.
A lesson learned
After medical school and an internship, he started a residency in 1974 at the University of California-San Francisco. Young doctors were assigned their rotations alphabetically based on their last names. He happened to get oncology.
Aspiring doctors viewed oncology, a relatively new specialty then, as too depressing because survival rates were poor, he said. At the time, U.S. deaths from all types of cancer numbered 199 per 100,000 population, compared with 181 in 2006, the most recent year for which figures are available, according to the National Center for Health Statistics.
The biggest killer was lung cancer. While overall rates have fallen only 9 percent since 1975, more patients live longer.
Von Hoff learned that while the cancer patients were very sick, there was always something he could do to help, be it alleviating pain or simply caring. He got hooked.
After his residency, he trained in oncology at the National Cancer Institute in Bethesda, Md. Colleagues who trained with him said his "off the charts" work ethic was apparent early on. While others went home in the evening, he would stay at the lab until well past midnight.
While he was training, he learned an important lesson that has guided him ever since.
A psychiatrist began shadowing him on the job, studying how young doctors respond to the loss of their patients.
While the psychiatrist observed him, Von Hoff learned from the psychiatrist during their conversations.
The psychiatrist taught him that no matter how much time he needed to spend with a patient, he should push all other concerns out of his mind.
"If you listen, they will help you help them," Von Hoff remembers the psychiatrist saying.
It wasn't easy. There was a tendency to think about the next appointment or an earlier patient. He really had to concentrate to do a good job of listening. But his listening became more focused, something that would benefit his research greatly within a few years.
The KFC factor
In the late 1970s, Von Hoff was recruited to start a new drug-development program at the University of Texas Health Science Center in San Antonio.
He studied anti-cancer drugs in the lab and then conducted clinical trials with those that showed potential. Outside of work, he and his wife, Ann, were raising two daughters and a son.
One day, around 1987, he was treating a man whose advanced-stage pancreatic cancer had spread to his liver. The pancreas, a pear-shaped organ behind the stomach, produces enzymes that aid digestion and regulate metabolism. Pancreatic cancer spreads quickly, with symptoms often not appearing until the tumor is too far advanced to operate.
Von Hoff started the man on an experimental drug called gemcitabine. During one visit to monitor his condition, the man's wife started scolding the doctor.
"Dr. Von Hoff, you're late again," she said as he walked into the room. "I've got to get my husband over to Kentucky Fried Chicken. He really likes to eat Kentucky Fried Chicken."
Von Hoff, always attentive, stopped short. People with pancreatic cancer often lose weight because the tumor kills their appetite. He flipped through the man's chart. The patient had gained weight rapidly, putting on 11 pounds.
"How are you feeling?" Von Hoff asked him.
"Geez, you know doc, I feel better. The pain is gone," the man said.
Von Hoff looked down and noticed the man wore Adidas track shoes.
"Walking a lot?" Von Hoff asked.
"Oh, I've got energy," the man said. "I got these new shoes."
All the signs, taken together, indicated for the first time that gemcitabine was proving effective in clinical trials for pancreatic cancer. The drug went on to get FDA approval and became the first to improve one-year survival rates for pancreatic cancer. It also was approved, in combination with other drugs, to treat breast, lung and ovarian cancer.
Gemcitabine works by inserting itself into the tumor's DNA, causing the tumor cells to get confused about how to reproduce. The man whom Von Hoff had treated lived about another year, when average survival was only two to three months.
When giving lectures to other doctors or students, Von Hoff recalls that moment in the exam room and urges the students to remember the "Kentucky Fried Chicken factor."
"The KFC factor is 'Listen to your patient,' " he says.
Ongoing challenges
In 1999, Von Hoff was recruited to the Arizona Cancer Center in Tucson. He continued his research there, and seven years ago began working at TGen in an emerging area of medicine known as genomics, in which DNA research of diseases is leading to advances in cancer treatment.
In applying genomics research to cancer, doctors analyze the molecular structure of the patient's tumor, trying to pinpoint vulnerabilities and come up with treatments to match.
Today, he and his team conduct clinical trials in partnership with Scottsdale Healthcare. More than 30 clinical drug trials are under way.
He sees patients in clinical trials every Monday. When they arrive, they are greeted in the lobby by oversized stuffed animals handpicked by Von Hoff. The animals help create a comfortable atmosphere for the adults in clinical trials.
Von Hoff deals with death all the time, but colleagues say his mood remains upbeat. His focus is on extending lives and learning something to help future patients.
"He's the spark plug and the bulldog, and the one who is always keeping the spirits up," said Mark Slater, Scottsdale Healthcare's vice president of research.
Von Hoff sees patients all day on Mondays. He returns to his Scottsdale home around 7 or 8 p.m., eats a salad at his desk there and goes back to work, dictating notes until 2 a.m.
He grabs a few hours of sleep and is up by 5 a.m.
Colleagues often open their e-mails in the morning and find messages sent by him overnight.
He credits good genes for being able to get by on little sleep; his mother is the same way.
When he is not at the clinic at the Virginia G. Piper Cancer Center in Scottsdale, he checks in with his lab, consults with doctors and nurses on patient cases and participates in conference calls about new cancer treatments and therapies. He also travels to medical conferences at which the latest cancer treatments are discussed.
His schedule is planned weeks in advance. But patients say he is never too busy to take their calls, even giving them his cellphone number.
Despite his and other research and new drug therapies, pancreatic cancer remains a formidable challenge.
Only 20 percent of people with pancreatic cancer are alive one year after being diagnosed. Less than 4 percent are still living after five years, according to the American Cancer Society.
Pancreatic cancer is the fourth-leading cause of cancer deaths in both males and females, with only lung, prostate, colon and breast cancer killing more people.
Von Hoff is the first to admit that progress to extend survival has been too slow.
Last year, his research got a boost. TGen, in partnership with the University of Pennsylvania, received a three-year, $18 million grant from a philanthropic group, Stand Up to Cancer, to develop tests to better understand the nutrients that allow pancreatic cells to grow and survive. The aim is to cut off the supply.
Von Hoff and his team also are conducting clinical trials that combine gemcitabine with another anti-cancer drug called nab-paclitaxel. Earlier this year, they reported a one-year survivorship of 52 percent, double the rate for patients who took only gemcitabine. A larger clinical study is under way.
Von Hoff's goal is to find a cure for pancreatic cancer before he retires.
If that doesn't happen, he hopes to have advanced the research far enough to set the stage for other scientists to find a cure.
He is optimistic that all cancers can be wiped out within 25 years.
"The advances are coming fast and furious," he said. "I'm not sure I will live to see it, but I know for sure my kids will."
Read more: http://www.azcentral.com/arizonarepublic/news/articles/2010/08/08/20100808valley-cancer-doctor.html#ixzz3B90hDyPS
bull
2 main treatments being used for ovarian cancer are...Carboplatin alone andCarboplatin with paclitaxel (Taxol)
Some of the other chemo drugs that are helpful in treating ovarian cancer include (in alphabetical order):
Albumin bound paclitaxel (nab-paclitaxel, Abraxane®)
Altretamine (Hexalen®)
Capecitabine (Xeloda®)
Cyclophosphamide (Cytoxan®)
Etoposide (VP-16)
Gemcitabine (Gemzar®)
Ifosfamide (Ifex®)
Irinotecan (CPT-11, Camptosar®)
Liposomal doxorubicin (Doxil®)
Melphalan
Pemetrexed (Alimta®)
Topotecan
Vinorelbine (Navelbine®)
bull
I saw that also...and was wondering about the ovarian cancer drug TD2 will be using...I guess we will find out soon enough..thanks for posting it...
bull
NUVILEX'S TIME HAS ARRIVED...2014 and 2015 will be amazing for this little bio and as soon as TD2 study is complete and results given...light will be shed on nvlx....
bull
NUVILEX IS DOING EVERYTHING RIGHT....It is just going to be a waiting game right now for a bit...
bull
Dr. Frost buying opk every day....
bull
NUVILEX is the ultimate HIDDEN GEM...
won't be that long until it comes out from under the radar...
bull
Nuvilex has evolved into such a different company Is that something from 2012...I guess I am missing the point......that is why I in my own personal opinion....feel like there are so many more long investors piling into this tiny bio...there are a lot of smart people out there...
bull
NUVILEX IS A HIDDEN GEM...and we know it...it takes insight that some don't have...to find a stock like this...so I don't care about the daily noise...my stocks that was in this stage 2 years ago have seeded our retirement very well...Nuvilex will be the one to put the icing on the top...you know ...I know it... and so do all the looooong term investors...
keep
Another thing that they are always missing and always have is that Nuvilex's CiaB Technology does not compete with any of the bio or pharma companies...they have drugs...we have the technology to make their patients lives extended and have a better quality of life by using CiaB with THEIR drug...and so companies that might be watching what Nuvilex is doing is not because they are worried about competition...they are watching because if all goes well like we expect to...they will be wanting to license CiaB...that is what it is all about...
bull
Real longs in Nuvilex are not worried about that ...ask any of them...truthfully they take that as an opportunity to buy a micro cap stock like Nuvilex at this pps...that is why you don't see them getting mad...instead they buy....today was a turning point that all long investors in Nuvilex have been waiting for patiently...and we can wait some more...Nuvilex is just getting started...they were smart to ditch the old and buy BioBlueBird....they won't look back and neither do the longs...not on old news...not on old Q's...not on old anything...today is the real start...watch...
bull
NUVILEX has MASSIVE POTENTIAL that cannot be ignored...
world renowned doctors...early trials under their belt...Dr. Von Hoff approaching Nuvilex to work with them...how much more could anyone want from a micro cap stock...unreal potential...
bull
LOOKING GREAT HERE AT NUVILEX STUDY UNDERWAY...just what Waggoner said last week...and a short lived mice study with Ciab and with a second new drug....
bull
A second group of mice will be treated with a drug normally used to treat ovarian cancer, and a third group will be administered that drug along with Nuvilex's Cell-in-a-Box® encapsulated live cells and ifosfamide combination.
did you see a a second group of mice will be treated with a drug normally used to treat ovarian cancer...and a third group will be administered that drug along with Nuvilex's Cell-in-a-Box® encapsulated live cells and ifosfamide combination....we get to see Ciab used with another drug...
Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid
Published: Aug 20, 2014 9:01 a.m. ET
0
SILVER SPRING, Md., Aug 20, 2014 (GLOBE NEWSWIRE via COMTEX) --
Nuvilex, Inc. (otcqb:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development's (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex's unique cancer treatment can slow the accumulation of fluid, known as "malignant ascites," in the abdomen that is characteristic of the growth of many abdominal tumors.
Kenneth L. Waggoner, CEO and President of Nuvilex, stated, "The start of these studies at TD2 is a banner day for Nuvilex. We are extremely gratified to have a prestigious organization such as TD2 performing these studies on our behalf. It should be noted that these studies represent the first time that any work, either preclinical or clinical, has been done in the United States with the Cell-in-a-Box® cellulose-based live cell encapsulation technology that has such exciting potential." Malignant ascites fluid in the abdomen contains cancer cells which can "seed" and form new tumors. Accumulation of this fluid is problematic for cancer patients and can cause significant discomfort. The current standard of care requires that malignant ascites fluid be removed from the abdomen of cancer patients at regular intervals.
In the studies being conducted by TD2, mice that have no immune system, and thus cannot reject foreign tissue from other species, will be injected with human ovarian cancer cells. These particular cells were chosen for these studies because: (i) they reproduce rapidly and form tumors; and (ii) the resultant tumors are proficient at producing malignant ascites fluid.
When the tumors have seeded in the abdomen, the mice will be randomized into four groups. One group of mice will be treated with Nuvilex's pancreatic cancer treatment consisting of the combination of Cell-in-a-Box® encapsulated live cells and the cancer prodrug ifosfamide (the encapsulated cells express an enzyme, CYP2B1, which converts ifosfamide into its cancer-killing form). A second group of mice will be treated with a drug normally used to treat ovarian cancer, and a third group will be administered that drug along with Nuvilex's Cell-in-a-Box® encapsulated live cells and ifosfamide combination. The remaining mice will serve as the "control" group for comparison purposes. The mice will be followed until humane endpoints have been reached. The time for this to occur for the treated mice will be compared to that for the control group of mice.
Nuvilex's CEO and President added, "We are confident that this work at TD2 will prove to be just the beginning of a long and fruitful journey for Nuvilex as we strive to develop our unique cancer treatment."
we will differ on cocp because you are a trader and I am a long..so be it...Frost is a long similar to Warren B...some people don't worry about the day to day trading of cocp or their other holdings...they buy and stick them away in a pile of stocks like me and then spend their time finding the next one instead of worrying about trading the last one...cocp...and this stock is just getting started...
bull
I own quite a few Frost stocks including cocp....I am not selling...he took this company that he was involved in and found a way to do a reverse merger with a company that needed help...and all got what they needed...this is not a stock to buy and then expect miraculous results from right off the bat...trade it or whatever...longs will own it..
bull